BioFactura

United States
Gas, Kansas, United States, 21701

Company profile

BioFactura company profile

BioFactura has developed the StableFast™ Biomanufacturing Platform, a novel system to rapidly generate stable NS0 cell lines for biopharmaceutical manufacturing. The elements of this system include a chemically-defined, serum- and cholesterol-free production medium and pre-adapted parental cells, modular expression vectors that utilize a patented selection strategy, and a proprietary growth supplement that permits rapid generation and cloning of cell lines. This platform is simple to use, fast, and productive. A clonal production cell line can be developed and scaled up to yield over one gram of product in less than eight weeks.

Business identity

Contact email
[email protected]
Phone number
(301)315-8002
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2001-01-01, Year

Headquarters

Postal code
21701
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
4
Total equity funding
$7.8M
Last funding
Grant / $1M / 2020-07-28
Last equity funding
Series B / $6M
Investors
5
Lead investors
4
Founders
1
Articles
26

Founders and investors

Founders

Darryl Sampey

Lead investors

Biomedical Advanced Research and Development Authority (BARDA)The University of Vermont Health NetworkU.S. Department of DefenseWilson Sonsini Goodrich & Rosati

Investors

Biomedical Advanced Research and Development Authority (BARDA)Jeffrey HausfeldThe University of Vermont Health NetworkU.S. Department of DefenseWilson Sonsini Goodrich & Rosati